EP0789560A1 - A novel pharmaceutical for oral administration comprising progresterone and a polyethyelene glycol together with an excipient - Google Patents

A novel pharmaceutical for oral administration comprising progresterone and a polyethyelene glycol together with an excipient

Info

Publication number
EP0789560A1
EP0789560A1 EP94925355A EP94925355A EP0789560A1 EP 0789560 A1 EP0789560 A1 EP 0789560A1 EP 94925355 A EP94925355 A EP 94925355A EP 94925355 A EP94925355 A EP 94925355A EP 0789560 A1 EP0789560 A1 EP 0789560A1
Authority
EP
European Patent Office
Prior art keywords
starch
progesterone
pharmaceutical composition
composition according
estradiol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94925355A
Other languages
German (de)
French (fr)
Inventor
Karen Susanne Gram
Annelise Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of EP0789560A1 publication Critical patent/EP0789560A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Definitions

  • a novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together with an excipient
  • the present invention relates to a pharmaceutical composition in the form of a dosage unit for oral administration of prog- esterone or of progesterone and estradiol.
  • Progesterone is a steroid hormone secreted by the ovaries in mammals. Its major biologic functions are to prepare the uterine endometrium for fertilization and implantation of a fertilized ovum and to support pregnancy. Also, when no con ⁇ ception occurs, progesterone plays an important role in the maturation of the uterine endometrium which preceeds the shedding of the epitelial layer thereof during the menstruel bleeding.
  • the amount of progesterone secreted per day by women varies during the menstrual cycle.
  • about 1 - 2 mg per day is secreted resulting in a serum level of approximately 0.1 - 1.5 ng/ l.
  • During the luteal phase about 10 - 20 mg per day is secreted resulting in a serum level of approximately 5.7 - 28.1 ng/ml.
  • the secretion of progesterone rises to several hundred mg per day.
  • Progesterone deficiency in women may i.a. lead to dys ⁇ functional uterine bleeding, amenorrhea, endometrial hyper- plasia and carcinoma, premenstruel tension and endometriosis.
  • progesterone is gen- erally found to have a low bioavailability. This fact to ⁇ gether with the fact that the first-pass liver metabolism of progesterone is very high has hitherto made oral ad ⁇ ministration of progesterone problematic. Rectal or vaginal suppositories provide modest levels of progesterone, but are esthetically displeasing to many women. Progesterone may also be administered by intramuscular injection. However, besides being painful, this route of administration is inconvenient because it is unsuited for self-care by the patient.
  • progesterone As a substitute for progesterone, a number of synthetic prog- estogens have been used in hormone replacement therapy for treating conditions resulting from progesterone deficiency and in oral contraceptives. Such synthetic agents can be tailored to have the desired properties as regards their ab- sorption and excretion. Although the biologic effects of some of these agents are very similar to the biologic effects of progesterone they are not identical and adverse reactions are well recognised. Thus, certain synthetic progestational agents possess an androgenic effect with a long term risk of virilisation and a risk of masculinisation of the foetus in the case of treatment during pregnancy. Other derivatives have a long term estrogenic effect. Contrary to progesterone, some of the synthetic progestational agents have no anti- estrogenic effect, anti-aldosteronic effect or anti-ovulatory effect.
  • vaginal tablets may, after vaginal insertion, form a sponge-like mass. Smaller amounts of super disintegrants may cause the formation of a gel ⁇ atinous sheath around the tablet. In both cases, the bio ⁇ availability is reduced.
  • starch disintegrant According to the Greco et al. patents, the optimum formulation for a vaginal tablet contains about 7% of corn starch. The patents contain no disclosure as to whether starch would have a favourable influence on the bioavailability of progesterone after oral administration.
  • One object of the present invention is to provide a phar ⁇ maceutical composition in the form of a dosage unit for oral administration of progesterone which composition has a favourable bioavailability.
  • Another object of the present invention is to provide a phar ⁇ maceutical composition in the form of a dosage unit for oral administration which is suitable for treating progesterone deficiency conditions.
  • a polyethylene glycol together with an excipient selected from the group comprising a starch, a starch component, a modified starch, a cellulose, a modified cellulose, pectin, and tragacanth has a favourable influence on the bioavailability of progesterone in dosage units for oral administration.
  • the present invention relates to a pharmaceutical composition in the form of a dosage unit for oral administration which composition com ⁇ prises progesterone and a polyethylene glycol together with an excipient selected from the group comprising a starch, a starch component, a modified starch, a cellulose, a modified cellulose, pectin, and tragacanth.
  • an excipient selected from the group comprising a starch, a starch component, a modified starch, a cellulose, a modified cellulose, pectin, and tragacanth.
  • the progesterone contained in the dosage unit is micronized.
  • the composition further comprises estradiol.
  • the amount of progesterone contained in each dosage unit is in the range of from about 10 mg to about 500 mg, more pre ⁇ ferred from about 20 mg to about 300 mg, most preferred from about 50 mg to about 225 mg.
  • the amount of estradiol contained in each dosage unit is in the range of from about 0.1 mg to about 5.0 mg, more pre ⁇ ferred from about 0.4 mg to about 2.0 mg.
  • the composition comprises a polyethylene glycol having an average molecular weight in the range of from about 1000 to about 10,000.
  • the composition comprises a polyethylene glycol having an average molecular weight of about 6000.
  • the composition comprises starch in the form of maize starch.
  • the composition comprises starch in the form of potato starch.
  • the composition comprises starch in the form of rice starch. According to another preferred embodiment of the invention, the composition comprises starch in the form of wheat starch.
  • the composition comprises starch in the form of tapioca starch.
  • the composition comprises a modified starch.
  • the composition comprises a starch component in the form of amylose.
  • the composition comprises a starch component in the form of amylopectin.
  • the amount of starch contained in the dosage unit constitutes from about 5% to about 75% by weight, more preferred from about 15% to about 50% by weight, most preferred from about 21% to about 30% by weight of the dosage unit.
  • the amount of progesterone contained in the dosage unit con ⁇ stitutes at least about 25%, more preferred at least 33% of the total weight of the dosage unit.
  • the composition is provided in the form of a dosage unit con- taining an amount of progesterone or of progesterone and estradiol which is appropriate to cover either the full daily need of a person to be treated or a simple fraction thereof such as one half or one third of the full daily need.
  • a dosage unit containing the full daily need is particularly preferred.
  • Progesterone can exist in two crystal modifications of equal physiologic activity and which are easily interconverte . As used in the present description, the designation progesterone comprehends both forms. In many references, progesterone is referred to as "natural progesterone". In the present de ⁇ scription, the designation progesterone comprehends prog ⁇ esterone of any origin, be it isolated from biologic ma ⁇ terial, synthetic, or semisynthetic. Progesterone can also be designated pregn-4-ene-3,20-dione.
  • the progesterone used in the compositions of the present in ⁇ vention is micronized. It is preferred that at least about 90% of the particles have a diameter less than 15 ⁇ m, that about 50% of the particles have a diameter less than 10 ⁇ m, and that about 10% of the particles have a diameter less than 5 ⁇ m.
  • estradiol means 170-estradiol, also designated cis-estradiol or estra- 1,3,5(10)-triene-3,17/3-diol.
  • Polyethylene glycols are liquid or solid polymers of the general formula H(OCH 2 CH 2 ) n oH wherein n is greater than or equal to 4.
  • each PEG is designated by a number which indicates its average molecular weight.
  • Starch is commonly used as an excipient in tablets. It usual- ly functions as a binder or as a disintegrant. The present inventors believe that solving the problem of improving the bioavailability of an orally administered drug compound by including a starch in the pharmaceutical composition con ⁇ taining it is new and surprising.
  • Maize starch, potato starch, rice starch, wheat starch, and tapioca starch are examples of starches which may find use in the present invention.
  • starches contain two different types of D-glucopyranose polymers, amylose and amylopectin.
  • a ylose is essentially a linear polymer of ⁇ -D-glucopyranosyl units linked (1 ⁇ 4) .
  • Amylopectin is a highly branched polymer of ⁇ -D-glucopyran ⁇ osyl units containing 1 ⁇ 4 links with 1 ⁇ 6 links at branch points.
  • starch is referred to in a generic way, it is preferred that amylose and amylo ⁇ pectin are also comprised by this designation.
  • starches for use in pharmaceutical compositions are pre- gelatinised or otherwise modified, e.g., by acid treatment, by oxidation or by hydroxyalkylation. It is preferred that such modified starches are also comprised by the designation starch when used in a generic way.
  • Cellulose too, in various forms, is commonly used as an ex ⁇ cipient in tablets. It usually functions as a binder, as a disintegrant or as a diluent.
  • Cellulose can be provided in natural form as a powder or in the form of fibres, e.g., iso ⁇ lated from fruits or vegetables or it can be chemically modi- fied, e.g., by alkylation, hydroxyalkylation or carb- oxymethylation.
  • Examples of chemically modified celluloses are methylcellulose (carmellose) , ethylcellulose, carb- oxymethylcellulose, hydroxypropylcellulose, and hydroxy- propylmethylcellulose.
  • the chemical modification may also comprise cross-linking. An example of this is croscarmellose.
  • cellulose is referred to in a generic way, it is preferred that all such modified celluloses are also comprised by the designation.
  • a PEG an excipient selected from the group comprising a starch, a starch component, a modified starch, a cellulose, a modified cellulose, pectin, and traga ⁇ canth, and optionally estradiol, the pharmaceutical com ⁇ positions according to the present invention may further com- prise one or more of the excipients commonly used in the art such as diluents, binders, disintegrants, lubricants, buffers and preservatives.
  • excipients are lactose, triglycerides, polyvinylpyrrolidones, gelatine, stearic acid, magnesium stearate, silica, and talcum powder.
  • tablets should only have to be taken once per day.
  • they should have a convenient size and they should not have a disagreeable smell or taste.
  • the absolute lower limit of the size of a tablet is, of course, determined by the amount of the active compound it has to contain. In practice, also a certain amount of ex- cipients will be necessary. If a tablet is very small, it is not convenient to handle. However, a very small amount of active compound can be administered in a tablet of a con ⁇ venient size by including a suitable amount of an inert diluent in the tablet formulation.
  • a very big tablet is not convenient to swallow, nor is it convenient to carry for example a month's supply in a hand ⁇ bag.
  • the total weight of a tablet should be from about 50 mg to about 500 mg, more preferred from about 100 mg to about 300 mg.
  • the kind and the amount of the excipients to be included in a pharmaceutical composition depends very much on the physico- chemical properties of the active compound to be administered and on the desired absorption profile. As already mentioned, inert excipients can be added in order to make a tablet bigger. Other excipients may be added to act as lubricants, binders, disintegrants, preservatives, in order to influence the rate of absorption or for other reasons. If a large amount of active compound is to be administered in a tablet and large amounts of excipients are called for in order to achieve the desired pharmaceutical technical properties of the composition, it can be a problem to keep the size of the tablet small enough to be convenient.
  • Example 4 of the 5 present specification discloses four different tablet for ⁇ mulations for 100 mg progesterone tablets. Two of the for ⁇ mulations, A and D, have almost the same bioavailability. However, the A-tablet weighs 800 mg which makes it very in ⁇ convenient in practice, whereas the D-tablet which weighs 10262.72 mg is very convenient in size.
  • tablets or cap ⁇ sules comprising the composition according to the invention can, for example, be provided by: 15 a) mixing progesterone with a starch, a starch com ⁇ ponent, or a modified starch, adding further ex ⁇ cipients, except lubricant, and optionally estradiol; b) granulating using a polyethylene glycol as a binder; c) optionally mixing a lubricant into the granulate; 20 and d) compressing the granulate thus obtained into tablets or or filling it into capsules.
  • Tablets according to the present invention may be coated or uncoated.
  • Coated tablets may be sugar coated or film coated 25 according to the known art.
  • the present invention relates to a composition for oral administration which comprises both progesterone and estradiol.
  • a composition can be used, i.a., in the treatment of perimenopausal disorders, in the 0 prevention or treatment of osteoporosis and in the treatment of other disorders which call for so-called opposed hormone replacement therapy.
  • a composition is used which contains progesterone as the sole hormone component.
  • Such a composition may find use, i.a., as an oral contraceptive and in the treatment of dis- orders caused by progesterone deficiency such as certain cases of infertility, premenstruel syndrome, and dys ⁇ functional bleeding. Further, such compositions may find use in peri-, and postmenopausal hormone replacement therapy.
  • a suitable composition for a tablet containing 100 mg of progesterone, and 1 mg of estradiol is as follows (amounts in mg) :
  • Estradiol and lactose are mixed and passed through a 300 mesh screen.
  • Progesterone, maize starch and croscarmellose sodium are added and the mixing is continued for further two minutes.
  • Polyethylene glycol 6000 is added to the powder mix- ture and the granulation is performed in a high speed mixer. The granules are passed through a 2400 mesh screen and cooled in a fluid bed. After cooling, the granules are passed through an 1100 mesh screen. Talcum powder and magnesium stearate are added followed by mixing for three minutes.
  • Tablets are compressed on a rotary tabletting machine.
  • pregelatinized maize starch instead of maize starch, pregelatinized maize starch, potato starch, pregelatinized potato starch, rice starch, or wheat starch can be used.
  • a suitable composition for a tablet containing 50 mg of progesterone, and 1 mg of estradiol is as follows (amounts in mg) :
  • Tablets are compressed on a rotary tabletting machine.
  • pregelatinized maize starch instead of maize starch, pregelatinized maize starch, potato starch, pregelatinized potato starch, rice starch, or wheat starch can be used.
  • a suitable composition for a tablet containing 100 mg of progesterone, and 2 mg of estradiol is as follows (amounts in mg) :
  • the granulate is prepared as described in Example 1.
  • Tablets are compressed on a rotary tabletting machine.
  • Tablet diameter 9 mm instead of maize starch, pregelatinized maize starch, potato starch, pregelatinized potato starch, rice starch, or wheat starch can be used.
  • AUC is the area under the curve showing the plasma concentration (in nM) as a function of time (hours) .
  • max is the maximum concentration (in nM) of progesterone in serum.
  • T mx is the time (hours) from the progesterone is administered until the maximum serum concentration is achieved.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

A pharmaceutical composition for oral administration of progesterone may, conveniently, contain a PEG, and a further excipient selected from the group comprising a starch, a cellulose, pecting, and tragacanth.

Description

A novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together with an excipient
FIELD OF THE INVENTION
The present invention relates to a pharmaceutical composition in the form of a dosage unit for oral administration of prog- esterone or of progesterone and estradiol.
BACKGROUND OF THE INVENTION
Progesterone is a steroid hormone secreted by the ovaries in mammals. Its major biologic functions are to prepare the uterine endometrium for fertilization and implantation of a fertilized ovum and to support pregnancy. Also, when no con¬ ception occurs, progesterone plays an important role in the maturation of the uterine endometrium which preceeds the shedding of the epitelial layer thereof during the menstruel bleeding.
The amount of progesterone secreted per day by women varies during the menstrual cycle. Thus, during the follicular phase about 1 - 2 mg per day is secreted resulting in a serum level of approximately 0.1 - 1.5 ng/ l. During the luteal phase about 10 - 20 mg per day is secreted resulting in a serum level of approximately 5.7 - 28.1 ng/ml. In the advanced stages of pregnancy, the secretion of progesterone rises to several hundred mg per day.
Progesterone deficiency in women may i.a. lead to dys¬ functional uterine bleeding, amenorrhea, endometrial hyper- plasia and carcinoma, premenstruel tension and endometriosis.
Immediately, the most obvious way to solve the problems related to progesterone deficiency would seem to be to administer progesterone to allow for the deficiency. However, when administered orally, non-micronized progesterone is gen- erally found to have a low bioavailability. This fact to¬ gether with the fact that the first-pass liver metabolism of progesterone is very high has hitherto made oral ad¬ ministration of progesterone problematic. Rectal or vaginal suppositories provide modest levels of progesterone, but are esthetically displeasing to many women. Progesterone may also be administered by intramuscular injection. However, besides being painful, this route of administration is inconvenient because it is unsuited for self-care by the patient.
As a substitute for progesterone, a number of synthetic prog- estogens have been used in hormone replacement therapy for treating conditions resulting from progesterone deficiency and in oral contraceptives. Such synthetic agents can be tailored to have the desired properties as regards their ab- sorption and excretion. Although the biologic effects of some of these agents are very similar to the biologic effects of progesterone they are not identical and adverse reactions are well recognised. Thus, certain synthetic progestational agents possess an androgenic effect with a long term risk of virilisation and a risk of masculinisation of the foetus in the case of treatment during pregnancy. Other derivatives have a long term estrogenic effect. Contrary to progesterone, some of the synthetic progestational agents have no anti- estrogenic effect, anti-aldosteronic effect or anti-ovulatory effect.
US patents Nos. 5,116,619 and 5,084,277 (Greco et al.) de¬ scribe a vaginal progesterone tablet and a method of making the same tablet, respectively. One of the stated objects of said invention is to provide a vaginal tablet having a pro- longed bioavailability. In the description, it is mentioned that the optimization of disintegration times for vaginal tablets is quite different from more traditional theoretical and practical approaches that are utilized for oral dosage forms. An important point, it is stated, is the choice of disintegrant. The differing amounts of moisture present in the mouth and in the vagina are primarily responsible for the different approaches required in these two regions. If large amounts of "super disintegrants" suitable in tablets for oral administration are used in vaginal tablets they may, after vaginal insertion, form a sponge-like mass. Smaller amounts of super disintegrants may cause the formation of a gel¬ atinous sheath around the tablet. In both cases, the bio¬ availability is reduced. These problems with vaginal tablets are overcome by using a starch disintegrant. According to the Greco et al. patents, the optimum formulation for a vaginal tablet contains about 7% of corn starch. The patents contain no disclosure as to whether starch would have a favourable influence on the bioavailability of progesterone after oral administration.
US patent No. 4,196,188 (Besins) discloses an orally administerable form of progesterone which is administered in a soft gelatine capsule containing an oil vehicle. Micronized progesterone crystallized and milled in a very specific way is used in the preparation of the capsules. It is stated that such micronized progesterone is unsuited for manufacturing compressed dosage forms such as tablets, since the tabletting process influences the particle size distribution in an un¬ favourable manner.
British patent application No. 2,091,552 (Carnrick) discloses a unit dosage of progesterone in conjunction with a suitable pharmaceutical carrier which may be cholesterol pivalate. No further details of the composition are given.
One object of the present invention is to provide a phar¬ maceutical composition in the form of a dosage unit for oral administration of progesterone which composition has a favourable bioavailability.
Another object of the present invention is to provide a phar¬ maceutical composition in the form of a dosage unit for oral administration which is suitable for treating progesterone deficiency conditions.
It is a further object of the present invention to provide a pharmaceutical composition in the form of a dosage unit for oral administration which dosage unit comprises progesterone and estradiol.
It is a further object of the present invention to provide a pharmaceutical composition for oral administration of pro¬ gesterone in which the weight of the progesterone constitutes a high percentage of the total weight of the tablet.
It is a still further object of the present invention to pro¬ vide a method of making a pharmaceutical composition of prog¬ esterone, optionally also containing estradiol, for oral ad¬ ministration having an improved bioavailability of the prog- esterone.
SUMMARY OF THE INVENTION
Surprisingly, it has turned out that a polyethylene glycol together with an excipient selected from the group comprising a starch, a starch component, a modified starch, a cellulose, a modified cellulose, pectin, and tragacanth has a favourable influence on the bioavailability of progesterone in dosage units for oral administration.
Accordingly, in its broadest aspect, the present invention relates to a pharmaceutical composition in the form of a dosage unit for oral administration which composition com¬ prises progesterone and a polyethylene glycol together with an excipient selected from the group comprising a starch, a starch component, a modified starch, a cellulose, a modified cellulose, pectin, and tragacanth. According to one preferred embodiment of the invention, the progesterone contained in the dosage unit is micronized.
According to another preferred embodiment of the invention, the composition further comprises estradiol.
According to another preferred embodiment of the invention, the amount of progesterone contained in each dosage unit is in the range of from about 10 mg to about 500 mg, more pre¬ ferred from about 20 mg to about 300 mg, most preferred from about 50 mg to about 225 mg.
According to another preferred embodiment of the invention, the amount of estradiol contained in each dosage unit is in the range of from about 0.1 mg to about 5.0 mg, more pre¬ ferred from about 0.4 mg to about 2.0 mg.
According to another preferred embodiment of the invention, the composition comprises a polyethylene glycol having an average molecular weight in the range of from about 1000 to about 10,000.
According to another preferred embodiment of the invention, the composition comprises a polyethylene glycol having an average molecular weight of about 6000.
According to another preferred embodiment of the invention, the composition comprises starch in the form of maize starch.
According to another preferred embodiment of the invention, the composition comprises starch in the form of potato starch.
According to another preferred embodiment of the invention, the composition comprises starch in the form of rice starch. According to another preferred embodiment of the invention, the composition comprises starch in the form of wheat starch.
According to another preferred embodiment of the invention, the composition comprises starch in the form of tapioca starch.
According to another preferred embodiment of the invention, the composition comprises a modified starch.
According to another preferred embodiment of the invention, the composition comprises a starch component in the form of amylose.
According to another preferred embodiment of the invention, the composition comprises a starch component in the form of amylopectin.
According to another preferred embodiment of the invention, the amount of starch contained in the dosage unit constitutes from about 5% to about 75% by weight, more preferred from about 15% to about 50% by weight, most preferred from about 21% to about 30% by weight of the dosage unit.
According to another preferred embodiment of the invention, the amount of progesterone contained in the dosage unit con¬ stitutes at least about 25%, more preferred at least 33% of the total weight of the dosage unit.
According to another preferred embodiment of the invention, the composition is provided in the form of a dosage unit con- taining an amount of progesterone or of progesterone and estradiol which is appropriate to cover either the full daily need of a person to be treated or a simple fraction thereof such as one half or one third of the full daily need. Most preferred is a dosage unit containing the full daily need. DETAILED DESCRIPTION OF THE INVENTION
Progesterone can exist in two crystal modifications of equal physiologic activity and which are easily interconverte . As used in the present description, the designation progesterone comprehends both forms. In many references, progesterone is referred to as "natural progesterone". In the present de¬ scription, the designation progesterone comprehends prog¬ esterone of any origin, be it isolated from biologic ma¬ terial, synthetic, or semisynthetic. Progesterone can also be designated pregn-4-ene-3,20-dione.
The progesterone used in the compositions of the present in¬ vention is micronized. It is preferred that at least about 90% of the particles have a diameter less than 15 μm, that about 50% of the particles have a diameter less than 10 μm, and that about 10% of the particles have a diameter less than 5 μm.
As used in the present description, the designation estradiol means 170-estradiol, also designated cis-estradiol or estra- 1,3,5(10)-triene-3,17/3-diol.
Polyethylene glycols (PEG's) are liquid or solid polymers of the general formula H(OCH2CH2)noH wherein n is greater than or equal to 4. In general, each PEG is designated by a number which indicates its average molecular weight.
Starch is commonly used as an excipient in tablets. It usual- ly functions as a binder or as a disintegrant. The present inventors believe that solving the problem of improving the bioavailability of an orally administered drug compound by including a starch in the pharmaceutical composition con¬ taining it is new and surprising.
Maize starch, potato starch, rice starch, wheat starch, and tapioca starch are examples of starches which may find use in the present invention.
Most starches contain two different types of D-glucopyranose polymers, amylose and amylopectin. A ylose is essentially a linear polymer of α-D-glucopyranosyl units linked (1→4) . Amylopectin is a highly branched polymer of α-D-glucopyran¬ osyl units containing 1→4 links with 1→6 links at branch points. When, in the present description, starch is referred to in a generic way, it is preferred that amylose and amylo¬ pectin are also comprised by this designation.
Some starches for use in pharmaceutical compositions are pre- gelatinised or otherwise modified, e.g., by acid treatment, by oxidation or by hydroxyalkylation. It is preferred that such modified starches are also comprised by the designation starch when used in a generic way.
Cellulose, too, in various forms, is commonly used as an ex¬ cipient in tablets. It usually functions as a binder, as a disintegrant or as a diluent. Cellulose can be provided in natural form as a powder or in the form of fibres, e.g., iso¬ lated from fruits or vegetables or it can be chemically modi- fied, e.g., by alkylation, hydroxyalkylation or carb- oxymethylation. Examples of chemically modified celluloses are methylcellulose (carmellose) , ethylcellulose, carb- oxymethylcellulose, hydroxypropylcellulose, and hydroxy- propylmethylcellulose. The chemical modification may also comprise cross-linking. An example of this is croscarmellose. When, in the present description, cellulose is referred to in a generic way, it is preferred that all such modified celluloses are also comprised by the designation.
Further to progesterone, a PEG, an excipient selected from the group comprising a starch, a starch component, a modified starch, a cellulose, a modified cellulose, pectin, and traga¬ canth, and optionally estradiol, the pharmaceutical com¬ positions according to the present invention may further com- prise one or more of the excipients commonly used in the art such as diluents, binders, disintegrants, lubricants, buffers and preservatives. Examples of such excipients are lactose, triglycerides, polyvinylpyrrolidones, gelatine, stearic acid, magnesium stearate, silica, and talcum powder.
One of the prerequisites which must be fulfilled in order to achieve a good compliance with the prescribed regimen in self care by the patient is that the medicine must be convenient to take. Thus, if possible, tablets should only have to be taken once per day. Preferably, they should have a convenient size and they should not have a disagreeable smell or taste.
The absolute lower limit of the size of a tablet is, of course, determined by the amount of the active compound it has to contain. In practice, also a certain amount of ex- cipients will be necessary. If a tablet is very small, it is not convenient to handle. However, a very small amount of active compound can be administered in a tablet of a con¬ venient size by including a suitable amount of an inert diluent in the tablet formulation.
A very big tablet is not convenient to swallow, nor is it convenient to carry for example a month's supply in a hand¬ bag. Most conveniently, the total weight of a tablet should be from about 50 mg to about 500 mg, more preferred from about 100 mg to about 300 mg.
The kind and the amount of the excipients to be included in a pharmaceutical composition depends very much on the physico- chemical properties of the active compound to be administered and on the desired absorption profile. As already mentioned, inert excipients can be added in order to make a tablet bigger. Other excipients may be added to act as lubricants, binders, disintegrants, preservatives, in order to influence the rate of absorption or for other reasons. If a large amount of active compound is to be administered in a tablet and large amounts of excipients are called for in order to achieve the desired pharmaceutical technical properties of the composition, it can be a problem to keep the size of the tablet small enough to be convenient. Example 4 of the 5 present specification discloses four different tablet for¬ mulations for 100 mg progesterone tablets. Two of the for¬ mulations, A and D, have almost the same bioavailability. However, the A-tablet weighs 800 mg which makes it very in¬ convenient in practice, whereas the D-tablet which weighs 10262.72 mg is very convenient in size.
The compositions according to the present invention are manu¬ factured by methods known in the art. Thus, tablets or cap¬ sules comprising the composition according to the invention can, for example, be provided by: 15 a) mixing progesterone with a starch, a starch com¬ ponent, or a modified starch, adding further ex¬ cipients, except lubricant, and optionally estradiol; b) granulating using a polyethylene glycol as a binder; c) optionally mixing a lubricant into the granulate; 20 and d) compressing the granulate thus obtained into tablets or or filling it into capsules.
Tablets according to the present invention may be coated or uncoated. Coated tablets may be sugar coated or film coated 25 according to the known art.
In one preferred embodiment, the present invention relates to a composition for oral administration which comprises both progesterone and estradiol. Such a composition can be used, i.a., in the treatment of perimenopausal disorders, in the 0 prevention or treatment of osteoporosis and in the treatment of other disorders which call for so-called opposed hormone replacement therapy. In another preferred embodiment according to the present in¬ vention, a composition is used which contains progesterone as the sole hormone component. Such a composition may find use, i.a., as an oral contraceptive and in the treatment of dis- orders caused by progesterone deficiency such as certain cases of infertility, premenstruel syndrome, and dys¬ functional bleeding. Further, such compositions may find use in peri-, and postmenopausal hormone replacement therapy.
The regimen for any patient to be treated with the com- positions according to the present invention should be de¬ termined by those skilled in the art.
The present invention is further illustrated by the following examples which, however, are not to be construed as limiting the scope of protection. The features disclosed in the fore- going description and in the following examples may, both separately and in any combination thereof, be material for realising the invention in diverse forms thereof.
EXAMPLE 1
Tablets containing 100 σ of progesterone and 1 mσ of estra- diol
A suitable composition for a tablet containing 100 mg of progesterone, and 1 mg of estradiol is as follows (amounts in mg) :
Progesterone 100 Estradiol 1
Maize starch 50.5
Lactose 30.5
Polyethylene glycol 6000 33
Croscarmellose sodium 9.2 Magnesium stearate 1.2
Talcum powder 4.6
Total 230.0 Estradiol and lactose are mixed and passed through a 300 mesh screen. Progesterone, maize starch and croscarmellose sodium are added and the mixing is continued for further two minutes. Polyethylene glycol 6000 is added to the powder mix- ture and the granulation is performed in a high speed mixer. The granules are passed through a 2400 mesh screen and cooled in a fluid bed. After cooling, the granules are passed through an 1100 mesh screen. Talcum powder and magnesium stearate are added followed by mixing for three minutes.
Tablets are compressed on a rotary tabletting machine.
Tablet mass 230 mg
Tablet diameter 9 mm
Instead of maize starch, pregelatinized maize starch, potato starch, pregelatinized potato starch, rice starch, or wheat starch can be used.
EXAMPLE 2
Tablets containing 50 g of progesterone and 1 g of estra¬ diol
A suitable composition for a tablet containing 50 mg of progesterone, and 1 mg of estradiol is as follows (amounts in mg) :
Progesterone 50
Estradiol 1
Maize starch 31.98 Lactose 11.97
Polyethylene glycol 6000 17.25
Croscarmellose sodium 4.8
Magnesium stearate 0.6
Talcum powder 2.4
Total 120.0 The granulate is prepared as described in Example 1.
Tablets are compressed on a rotary tabletting machine.
Tablet mass 120.0 mg
Tablet diameter 8 mm
Instead of maize starch, pregelatinized maize starch, potato starch, pregelatinized potato starch, rice starch, or wheat starch can be used.
EXAMPLE 3
Tablets containing 100 g of progesterone and 2 mg of estra- diol
A suitable composition for a tablet containing 100 mg of progesterone, and 2 mg of estradiol is as follows (amounts in mg) :
Progesterone 100 Estradiol 2
Maize starch 50.0
Lactose 30.0
Polyethylene glycol 6000 33.05
Croscarmellose sodium 9.2 Magnesium stearate 1.15
Talcum powder 4.6
Total 230.0
The granulate is prepared as described in Example 1.
Tablets are compressed on a rotary tabletting machine.
Tablet mass 230.0 mg
Tablet diameter 9 mm Instead of maize starch, pregelatinized maize starch, potato starch, pregelatinized potato starch, rice starch, or wheat starch can be used.
EXAMPLE 4 Pharmacokinetic results of the study of progesterone ab¬ sorption in women
Four different tablet formulations containing 100 mg of progesterone and 2 mg of estradiol have been compared in pharmacokinetic absorption studies in healthy postmenopausal women. The composition of the tablets used are given in Table 1 and the pharmacokinetic data of the four formulations are summarized in Tabel 2.
Table 1
Constituents A B C D per tablet
Progesterone 100 mg 100 mg 100 mg 100 mg
PEG 6000 43.5 mg 21.7 mg 63.09 mg
Kollidon k25 1.4 mg 1.4 mg
Kollidon va64 46.5 mg
Corn starch 320.0 mg 18.45 mg 18.45 mg 65.66 mg
Stearic acid 21,7 mg
Gelatine 0.5 mg 0.5 mg 0.5 mg
Lactose 320.0 mg 18.45 mg 18.45 mg 18.45 mg
Estradiol 2.00 mg 2.00 mg 2.00 mg 2.00 mg
Collodial 2.0 mg 2.0 mg 2.63 mg silica
Croscarmel¬ 9.9 mg 9.9 mg 8.48 mg lose sodium
Magnesium 4.20 mg 0.98 mg 0.98 mg 1.51 mg stearate
Talcum powder 8.00 mg 0.4 mg 0.4 mg 0.4 mg
Gross weight 800 mg 197.6 mg 197.6 mg 262.72 mg Table 2
Formulation Number of AUC Mean Cmax Mean Tmax Mean patients (nM x h) (nM) (h)
A 16 363.2 249.5 1.7
B 16 159.0 38.9 2.3
C 15 54.6 14.2 2.3
D 8 392.2 269.8 1.6
In Table 2, AUC is the area under the curve showing the plasma concentration (in nM) as a function of time (hours) . max is the maximum concentration (in nM) of progesterone in serum. Tmx is the time (hours) from the progesterone is administered until the maximum serum concentration is achieved.
As it appears from Table 2, the pharmacokinetic properties of the formulations A and D are very similar. However, in the case of formulation A a tablet containing 100 mg of prog¬ esterone weighs 800 mg and is thus far too big to be con¬ venient for ordinary use. In the case of formulation D a tablet containing 100 mg of progesterone weighs 262.72 mg which is very convenient.

Claims

1. A pharmaceutical composition for oral ad¬ ministration which comprises micronized progesterone, a poly¬ ethylene glycol, and an excipient selected from the group
5 comprising a starch, a starch component, a modified starch, a cellulose, a modified cellulose, pectin, and tragacanth.
2. A pharmaceutical composition according to claim 1 which further comprises estradiol.
3. A pharmaceutical composition according to claim 1 ιo or 2 wherein the amount of progesterone is in the range of from about 10 mg to about 500 mg per dosage unit.
4. A pharmaceutical composition according to claim 2 or 3 wherein the amount of estradiol is in the range of from about 0.1 mg to about 5.0 mg per dosage unit.
155. A pharmaceutical composition according to any one of the preceding claims comprising a starch which is selected from the group comprising maize starch, potato starch, rice starch, wheat starch, and tapioca starch.
6. A pharmaceutical composition according to any one 20 of the claims 1 to 4 comprising a starch component selected from the group comprising amylose and amylopectin.
7. A pharmaceutical composition according to any one of the claims 1 to 4 comprising a modified starch.
8. A pharmaceutical composition according to any one 25 of the preceding claims wherein the amount of starch con¬ stitutes from about 5% to about 75%, more preferred from about 15% to about 50% by weight, most preferred from about 21% to about 30% by weight of the dosage unit.
9. A method of making a pharmaceutical composition of progesterone for oral administration having an improved bioavailability, comprising the following steps:
a) mixing micronized progesterone with an excipient selected from the group comprising a starch, a starch component, a modified starch, a cellulose, a modified cellulose, pectin, and tragacanth, adding further ex¬ cipients, and optionally estradiol;
b) granulating using a polyethylene glycol as a binder;
c) optionally mixing a lubricant into the granulate; and
d) compressing the granulate thus obtained into tablets or filling it into capsules.
EP94925355A 1993-08-20 1994-08-19 A novel pharmaceutical for oral administration comprising progresterone and a polyethyelene glycol together with an excipient Withdrawn EP0789560A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK93950A DK95093D0 (en) 1993-08-20 1993-08-20 PHARMACEUTICAL FORMULA CONTAINING A HORMON
DK950/93 1993-08-20
PCT/DK1994/000310 WO1995005807A1 (en) 1993-08-20 1994-08-19 A novel pharmaceutical for oral administration comprising progesterone and a polyethylene glycol together with an excipient

Publications (1)

Publication Number Publication Date
EP0789560A1 true EP0789560A1 (en) 1997-08-20

Family

ID=8099329

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94925355A Withdrawn EP0789560A1 (en) 1993-08-20 1994-08-19 A novel pharmaceutical for oral administration comprising progresterone and a polyethyelene glycol together with an excipient

Country Status (17)

Country Link
EP (1) EP0789560A1 (en)
JP (1) JPH09501682A (en)
KR (1) KR960703570A (en)
CN (1) CN1132478A (en)
AU (1) AU7530594A (en)
BR (1) BR9407306A (en)
CA (1) CA2169840A1 (en)
CZ (1) CZ42596A3 (en)
DK (1) DK95093D0 (en)
FI (1) FI960749A (en)
HU (1) HUT74167A (en)
LT (1) LT4043B (en)
NO (1) NO960653D0 (en)
NZ (1) NZ271617A (en)
PL (1) PL313113A1 (en)
SK (1) SK19396A3 (en)
WO (1) WO1995005807A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753184B2 (en) * 1998-06-30 2002-10-10 Telefonaktiebolaget Lm Ericsson (Publ) Method for operational changes authorization on a mobile phone

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772617B1 (en) * 1997-12-19 2001-03-09 Besins Iscovesco Lab PROGESTERONE TABLET AND PROCESS FOR THE PREPARATION THEREOF
FR2775599B1 (en) 1998-03-09 2001-08-17 Besins Iscovesco Lab PHARMACEUTICAL COMPOSITION BASED ON SYNTHESIS NATURAL PROGESTERONE AND OESTRADIOL AND PROCESS FOR PREPARING THE SAME
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
KR100857344B1 (en) * 1999-08-31 2008-09-05 바이엘 쉐링 파마 악티엔게젤샤프트 Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US6544553B1 (en) 1999-12-28 2003-04-08 Watson Pharmaceuticals, Inc. Dosage forms and methods for oral delivery of progesterone
FI20002768A (en) * 2000-12-18 2002-06-19 Licentia Oy Entero-coated pharmaceutical compositions and their preparation
CA2479295A1 (en) * 2002-03-14 2003-09-25 Thomas C. Ho Progesterone oral drug delivery system
DE602004016311D1 (en) * 2003-04-29 2008-10-16 Organon Nv PROCESS FOR FIXING AT WHICH AN ANTI SOLVENT IS USED
DE602006007453D1 (en) 2005-04-28 2009-08-06 Wyeth Corp COMPOSITIONS WITH MICRONIZED TANAPROGET
AT12800U1 (en) * 2007-11-05 2012-11-15 Bayer Schering Pharma Ag A pharmaceutical preparation for use in the oral contraception of lactose intolerant women
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (en) 2011-11-23 2021-09-02 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
MX2016014281A (en) 2014-05-22 2017-02-22 Therapeuticsmd Inc Natural combination hormone replacement formulations and therapies.
US20170035781A1 (en) 2015-06-22 2017-02-09 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862311A (en) * 1971-04-12 1975-01-21 Ciba Geigy Corp Novel method of enhancing progestational endometrial proliferation with progesterone
FR2408345A1 (en) 1976-11-30 1979-06-08 Besins Jean Louis NEW COMPOSITION WITH ANTI-CONCEPTIONAL ACTION
GB2091552A (en) 1980-09-09 1982-08-04 Carnrick G W Ltd Use of progesterone for the treatment of post-menopausal women
US4963540A (en) * 1986-04-16 1990-10-16 Maxson Wayne S Method for treatment of premenstrual syndrome
US5116619A (en) 1988-08-30 1992-05-26 Lee Roy Morgan Vaginal progesterone tablet
US5084277A (en) 1988-08-30 1992-01-28 Greco John C Vaginal progesterone tablet
WO1990008537A1 (en) * 1989-02-06 1990-08-09 Abbott Laboratories Pharmaceutical compositions for oral administration
US5223268A (en) * 1991-05-16 1993-06-29 Sterling Drug, Inc. Low solubility drug-coated bead compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9505807A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU753184B2 (en) * 1998-06-30 2002-10-10 Telefonaktiebolaget Lm Ericsson (Publ) Method for operational changes authorization on a mobile phone

Also Published As

Publication number Publication date
CZ42596A3 (en) 1996-06-12
LT96010A (en) 1996-06-25
FI960749A0 (en) 1996-02-19
PL313113A1 (en) 1996-06-10
FI960749A (en) 1996-02-19
LT4043B (en) 1996-09-25
CA2169840A1 (en) 1995-03-02
HUT74167A (en) 1996-11-28
NZ271617A (en) 1996-11-26
KR960703570A (en) 1996-08-31
HU9600376D0 (en) 1996-04-29
SK19396A3 (en) 1997-03-05
NO960653L (en) 1996-02-19
BR9407306A (en) 1996-10-08
CN1132478A (en) 1996-10-02
NO960653D0 (en) 1996-02-19
DK95093D0 (en) 1993-08-20
AU7530594A (en) 1995-03-21
WO1995005807A1 (en) 1995-03-02
JPH09501682A (en) 1997-02-18

Similar Documents

Publication Publication Date Title
EP0789560A1 (en) A novel pharmaceutical for oral administration comprising progresterone and a polyethyelene glycol together with an excipient
RU2479306C2 (en) Pharmaceutical composition containing tetrahydrofolic acid
CA2470703C (en) Oral pharmaceutical products containing 17.beta.-estradiol-3-lower alkanoate, method of administering the same and process of preparation
JPH04290830A (en) Prescribed contraceptive
CZ296387B6 (en) Contraceptive preparation
JP2005526083A (en) Progesterone oral drug delivery system
KR100623788B1 (en) Novel hormonal composition and the use thereof
JP2002509524A (en) Hormone composition comprising an estrogen compound and a progesterone-like compound
JP2000515888A (en) Birth control pills
AU747710B2 (en) Progestogen-antiprogestogen regimens
EP0322020A1 (en) Pharmaceutical dosage unit for treating climacteric complaints and osteoporosis
JP2001516720A (en) Oral contraceptive formulation having progestin / estrogen first phase and progestin second phase
JP2000515889A (en) Biphasic contraceptive method and kit comprising a mixture of progestin and estrogen
RU2258512C2 (en) Contraceptive medicinal agent based on gestagen and estrogen and method for its preparing
TW200306846A (en) Hormone replacement therapy
EP1178807B1 (en) Use of org 33245 in combined intermittent hormone therapy and contraception
CN101623287B (en) Novel drospirenone analogue medicinal composition for treating menopausal syndrome
CN1950092A (en) Management of breakthrough bleeding in extended hormonal contraceptive regimens
CN101623288A (en) Medicinal composition containing drospirenone analogue for treating menopausal syndrome

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960320

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19990202